Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Reply to S. Nagai et al [Letter]

Grimwade, D., Jovanovic, J. V., Hills, Robert Kerrin, Solomon, E., Lo-Coco, F., Wheatley, K. and Burnett, Alan Kenneth 2009. Reply to S. Nagai et al [Letter]. Journal of Clinical Oncology 28 (4) , e63-e64. 10.1200/JCO.2009.25.0522

Full text not available from this repository.


Nagai et al1 highlight some pertinent issues related to current treatment approaches to acute promyelocytic leukemia (APL). In common with data from other cooperative groups, the recent study by the European APL Group reported by Kelaidi et al2 shows how heightened awareness of APL as a medical emergency demanding prompt administration of all-trans-retinoic acid (ATRA) and aggressive coagulation support—coupled with greater experience in prevention and management of treatment-related complications, including differentiation syndrome—has led to reductions in rates of induction death, particularly in patients with higher presenting WBC counts. Such measures were similarly implemented in the MRC AML15 (Medical Research Council [London, United Kingdom] Acute Myeloid Leukemia) trial,3 in accordance with the International European LeukemiaNet guidelines.4 However, when comparing results from different cooperative groups, it is also important to recognize that different trial entry criteria can result in large differences in reported rates of induction death.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: American Society of Clinical Oncology
ISSN: 0732-183X
Last Modified: 19 Oct 2019 02:51

Actions (repository staff only)

Edit Item Edit Item